UltrafleXtreme MALDI-TOF/TOF is to be coupled with the MassInsight platform.
Bruker has announced a collaboration with Nextval for high-throughput screening of drugs using Bruker’s ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval’s MassInsight technology.
The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam IITM laser with its Perpetual Ion Source for low concentration high-throughput screening.
Bruker’s CompassTM software allows integration with Nextval’s screening technology to maximise sample density and reduce sample analysis costs.
Nextval’s MassInsight screening technology is based on novel surface chemistries coupled with microarray acoustic deposition methods.
It is able to prepare high density arrays with little to no sample preparation of substrates.
Dr. Matthew Greving, CSO of Nextval, stated: “The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity.”
Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialise their MassInsight technology for high-throughput enzyme assays.
To read more about ultrafleXtreme MALDI-TOF/TOF please click on the link above.
